Shah, K. U., Rider, J., Pindale, R., Zugman, M., Jaime-Casas, S., Goes, V. A. D., Moradi, A., Salgia, N., Zang, P. D., Castro, D. V., Mercier, B., Zhang, G., Li, Y., Dizman, N., Hsu, J., Yip, W., Tripathi, A., Nguyen, C. B., Chehrazi-Raffle, A., Pal, S. K. (2026). Biomarker-defined outcomes in metastatic clear cell renal cell carcinoma (mccRCC) receiving first-line (1L) immune checkpoint inhibitor-based therapy.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.4546